ATE192166T1 - Antikörper gegen allogene und xenogene proteine, ihre verwendung in diagnose und therapie und verfahren zu ihrer bestimmung - Google Patents

Antikörper gegen allogene und xenogene proteine, ihre verwendung in diagnose und therapie und verfahren zu ihrer bestimmung

Info

Publication number
ATE192166T1
ATE192166T1 AT95936566T AT95936566T ATE192166T1 AT E192166 T1 ATE192166 T1 AT E192166T1 AT 95936566 T AT95936566 T AT 95936566T AT 95936566 T AT95936566 T AT 95936566T AT E192166 T1 ATE192166 T1 AT E192166T1
Authority
AT
Austria
Prior art keywords
xenogene
allogene
diagnostics
antibodies
therapy
Prior art date
Application number
AT95936566T
Other languages
English (en)
Inventor
Alberto Bartorelli
Original Assignee
Zetesis Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zetesis Spa filed Critical Zetesis Spa
Application granted granted Critical
Publication of ATE192166T1 publication Critical patent/ATE192166T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95936566T 1994-11-04 1995-10-30 Antikörper gegen allogene und xenogene proteine, ihre verwendung in diagnose und therapie und verfahren zu ihrer bestimmung ATE192166T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT94MI002238A IT1276860B1 (it) 1994-11-04 1994-11-04 Anticorpi naturali contro proteine allogeniche e xenogeniche e metodi per la loro determinazione
PCT/EP1995/004239 WO1996014340A1 (en) 1994-11-04 1995-10-30 Antibodies against allogenic and xenogenic proteins, their use in diagnosis and therapy and methods for the determination thereof

Publications (1)

Publication Number Publication Date
ATE192166T1 true ATE192166T1 (de) 2000-05-15

Family

ID=11369803

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95936566T ATE192166T1 (de) 1994-11-04 1995-10-30 Antikörper gegen allogene und xenogene proteine, ihre verwendung in diagnose und therapie und verfahren zu ihrer bestimmung

Country Status (26)

Country Link
EP (1) EP0789716B1 (de)
JP (1) JPH10508591A (de)
KR (1) KR100426029B1 (de)
CN (1) CN1046737C (de)
AR (1) AR002243A1 (de)
AT (1) ATE192166T1 (de)
AU (1) AU690756B2 (de)
BR (1) BR9509556A (de)
CA (1) CA2204380A1 (de)
CZ (1) CZ288322B6 (de)
DE (1) DE69516534T2 (de)
DK (1) DK0789716T3 (de)
ES (1) ES2147617T3 (de)
FI (1) FI971879L (de)
GR (1) GR3033956T3 (de)
HU (1) HUT76880A (de)
IL (1) IL115862A (de)
IT (1) IT1276860B1 (de)
NO (1) NO972046L (de)
NZ (1) NZ295171A (de)
PL (1) PL181115B1 (de)
PT (1) PT789716E (de)
RU (1) RU2160445C2 (de)
TR (1) TR199501353A2 (de)
WO (1) WO1996014340A1 (de)
ZA (1) ZA959255B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283634B1 (it) * 1996-05-10 1998-04-23 Zetesis Spa Un metodo citofluorimetrico per la determinazione nel siero di anti- corpi anti-antigene tumorali
US20010014471A1 (en) * 1999-04-15 2001-08-16 Vytautas Naktinis Recombinant protein and its use in therapy and diagnostics
CN100516876C (zh) * 2002-11-21 2009-07-22 惠氏公司 用于诊断肾细胞癌(rcc)和其他实体瘤的方法
IT201600127428A1 (it) * 2016-12-16 2018-06-16 Cusani Alberto Bartorelli Nuova proteina ricombinante uk 114 in forma stabile polimerica per uso nella terapia, nella diagnostica e nella prevenzione di neoplasie maligne
IT201900022203A1 (it) * 2019-11-26 2021-05-26 Cusani Alberto Bartorelli Proteine uk 114 da salmone per uso nella terapia, nella diagnostica e nella prevenzione di neoplasie maligne

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO861491L (no) * 1985-04-22 1986-10-23 Hybritech Inc Antistoff, fremgangsmaate for dets fremstilling og anvendelse for deteksjon og diagnose av canser.
SU1603301A1 (ru) * 1987-12-22 1990-10-30 Карагандинский государственный медицинский институт Способ определени концентрации иммуноглобулинов в биологической жидкости
IT1244879B (it) * 1990-12-11 1994-09-12 Alberto Bartorelli Estratti da tessuti animali, utili in terapia e in diagnostica.

Also Published As

Publication number Publication date
EP0789716A1 (de) 1997-08-20
TR199501353A2 (tr) 1996-06-21
ZA959255B (en) 1996-05-29
NZ295171A (en) 1998-07-28
AU690756B2 (en) 1998-04-30
CN1166838A (zh) 1997-12-03
CN1046737C (zh) 1999-11-24
IT1276860B1 (it) 1997-11-03
DK0789716T3 (da) 2000-10-09
IL115862A0 (en) 1996-01-31
FI971879A7 (fi) 1997-06-24
GR3033956T3 (en) 2000-11-30
MX9703191A (es) 1997-07-31
ITMI942238A1 (it) 1996-05-04
KR970707161A (ko) 1997-12-01
HUT76880A (en) 1997-12-29
CZ288322B6 (en) 2001-05-16
AU3845395A (en) 1996-05-31
NO972046D0 (no) 1997-05-02
NO972046L (no) 1997-05-02
ES2147617T3 (es) 2000-09-16
DE69516534D1 (de) 2000-05-31
RU2160445C2 (ru) 2000-12-10
PL319878A1 (en) 1997-09-01
KR100426029B1 (ko) 2004-07-31
DE69516534T2 (de) 2000-11-30
ITMI942238A0 (it) 1994-11-04
FI971879L (fi) 1997-06-24
PT789716E (pt) 2000-09-29
WO1996014340A1 (en) 1996-05-17
BR9509556A (pt) 1997-09-16
JPH10508591A (ja) 1998-08-25
PL181115B1 (pl) 2001-05-31
EP0789716B1 (de) 2000-04-26
FI971879A0 (fi) 1997-05-02
IL115862A (en) 2001-06-14
CA2204380A1 (en) 1996-05-17
CZ131497A3 (en) 1997-12-17
AR002243A1 (es) 1998-03-11

Similar Documents

Publication Publication Date Title
DE10399006I1 (de) Tetracyclische derivate Verfahren zu ihrer Herstellung und ihre Verwendung
DE69531705D1 (de) Feine Zinkoxid-Teilchen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69722988D1 (de) Lithiumnickelverbundoxid, Verfahren zu seiner Herstellung und seine Verwendung
DE69733588D1 (de) Laminat und Verfahren zu seiner Herstellung
ATE206131T1 (de) Phosphonomonoesternnukleinsäuren, verfahren zu ihrer herstellung und ihre verwendung
AU3878697A (en) Identification of abnormalities in the expression of t and cell antigen receptors as indicators of disease diagnosis, prognosis and therapeutic predictors
DE69714475D1 (de) Neue (alpha-aminophosphino) peptide, verfahren zu ihrer herstellung und ihre therapeutische verwendung
DE69328301D1 (de) Diagnostisches verfahren zur bestimmung, ob die entbindung bevorsteht, und reagenzkit zur verwendung dafür
DE59802412D1 (de) Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE59701378D1 (de) Neue lederbehandlungsmittel, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung foggingarmer leder
DE69832784D1 (de) Fluorpolymere, verfahren zu ihrer herstellung und ihre verwendung
ATE192166T1 (de) Antikörper gegen allogene und xenogene proteine, ihre verwendung in diagnose und therapie und verfahren zu ihrer bestimmung
DE59506347D1 (de) Zirkondioxidpulver, Verfahren zu seiner Herstellung und Verwendung
DE59010759D1 (de) 3-Aminopyrrole, Verfahren zu ihrer Herstellung und ihre Verwendung als Antikonvulsiva
DE3689868D1 (de) Monoklonale Antikörper gegen menschliches Plasma-Prekallikrein und Verfahren zu ihrer Herstellung und Verwendung.
DE69706157D1 (de) Diarylmethylidenefuran-derivate, verfahren zu deren herstellung und ihre verwendungen in therapie
DE59401442D1 (de) Wasser-in-Öl-Polymeremulsionen, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69529787D1 (de) Testsatz und Methode für eine Bestimmung durch kompetitive spezifische Bindung
DE59800568D1 (de) Benzoxazindionderivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE59209008D1 (de) 2-Fluorpyrazine, Verfahren zu ihrer Herstellung und ihre Verwendung in flüssigkristallinen Mischungen
DE59700950D1 (de) 5-Z-Octenylester, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69735760D1 (de) Antikörper gegen menschliches lect2, zellen die diesen produzieren und verfahren und kit zu dessen bestimmung
DE69506944D1 (de) 1-Phenyl-1-cyano-C5-C7-Alkane, ihre organoleptische Verwendung und Verfahren zu deren Herstellung
DE59911949D1 (de) Substituierte sulfonylcyanamide, verfahren zu ihrer herstellung und ihre verwendung als medikament
DE68926487D1 (de) Vermiculit-Dispersionen und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee